Last reviewed · How we verify
Vinostatin (ZINOSTATIN)
Vinostatin (generic name: ZINOSTATIN) is a zinostatin drug. It is currently in Phase 2 development.
Zinostatin works by inhibiting cell growth and inducing apoptosis in cancer cells.
Vinostatin is a small molecule with the synonyms HOLONEOCARZINOSTATIN, NEOCARZINOSTATIN, NSC-157365, NSC-69856, ZINOSTATIN, and ZINOSTATIN. It has been studied in clinical trials for various conditions, including Irritable Bowel Syndrome (IBS), Functional Gastrointestinal Disorders, PCI patients, DAPT patients, and those undergoing hip fracture surgeries.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 2 attrition
-2.0pp
Oncology drugs have higher Phase 2-to-Phase 3 attrition than average — many fail to show OS benefit in larger studies.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | ZINOSTATIN |
|---|---|
| Drug class | zinostatin |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells are like a city with too many people. Zinostatin helps to slow down the growth of new buildings (cells) and eventually causes some of the old buildings to be torn down (apoptosis), which can help to control the spread of cancer.
Approved indications
Common side effects
Key clinical trials
- Comparison of Cardiovascular Risks Between Hip Fracture Surgery With Continued DAPT（Dual Antiplatelet Therapy ） Within 6 Weeks vs After 6 Weeks Post-PCI（Percutaneous Coronary Intervention）: A Prospective Observational Cohort Study
- To Compare Influence of Breakfast With and Without Sweeteners on Postprandial Glycemic Response and Appetite-Satiety Sensation in Subjects With Type 1 Diabetes (NA)
- Effect of a Diet Without Non-caloric Sweeteners on Gastrointestinal Symptoms in Patients With IBS and Dyspepsia (NA)
- Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma (PHASE3)
- Electrodiagnostic Parameters in Patients With Impaired Glucose Tolerance and Diabetes Mellitus
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vinostatin CI brief — competitive landscape report
- Vinostatin updates RSS · CI watch RSS
Frequently asked questions about Vinostatin
What is Vinostatin?
How does Vinostatin work?
What is the generic name of Vinostatin?
What drug class is Vinostatin in?
What development phase is Vinostatin in?
Related
- Drug class: All zinostatin drugs
- Therapeutic area: All drugs in Oncology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing